Metastatic renal cell carcinoma

摘要: Patients with renal cell cancer (RCC) develop metastatic spread in approximately 33% of cases. The clinical management patients RCC is complicated by the lack significant efficacy from available therapies. Common sites metastases include lung, liver, bone, brain, and adrenal gland, case reports detailing capacity to appear almost anywhere body. More than one organ system often involved process. Metastases may be found at diagnosis or some interval after nephrectomy. Approximately 20% 50% will eventually disease A shorter between nephrectomy development associated a poorer prognosis. face dismal prognosis, median survival time only 6 12 months 2-year rate 10% 20%. Recent advances biologic response modifier therapy have brought new hope small percentage who respond this rekindled interest cytoreductive as an integral part these patients.